Pain Management

Albert Dahan, MD, PhD, discusses how cebranopadol could fit into the broader landscape of pain management therapies.

“By encouraging active self-management using health coaching principles, the WalkBack intervention might be able to reduce the prevalence of recurrent low back pain and associated burden on health care systems,” wrote investigators.

Mark Garofoli combined personal anecdotes with professional expertise to deliver a compelling presentation on kidney stone pain at this year’s PAINWeek National Conference.

Albert Dahan, MD, PhD, discusses recent data on Tris Pharma’s first-in-class dual-NMR agonist and how it will fit into the broader landscape of pain management therapies.

Albert Dahan, MD, PhD, professor of anesthesiology at Leiden University Medical Center, talks about the first-in-class dual-NMR agonist cebranopadol.

The “cuddle hormone” plays a powerful role in human behavior and may be an additional option to treat pain and manage opioid addiction.

“Reducing abdominal adiposity may be considered a target for chronic pain management, particularly in those with pain in multiple sites and widespread pain,” wrote investigators.

Whereby gastroparesis can hinder the absorption of oral medications in the stomach, Tonix Pharmaceuticals is promoting alternative migraine treatments that bypass the digestive system.

Tris Pharma will examine the efficacy and safety of cebranopadol in the ALLEVIATE-1 and ALLEVIATE-2 studies.

Focus group participants were receptive to using eHealth tools, but noted several barriers such as cost and availability.

Researchers conducted a systematic review of literature exploring the misuse of opioid prescriptions for patients with chronic non-cancer pain.

Mark Garofoli delves deeper into the challenges men face when it comes to acknowledging pain, underscoring the critical need to dismantle the surrounding stigma.

In a recent conversation with Drug Topics on Over the Counter, Mark Garofoli discusses why men avoid seeking medical help for pain, as well as potential solutions.

The investigational oral, selective NaV1.8 pain signal inhibitor from Vertex Pharmaceuticals demonstrated a favorable benefit/risk profile in 3 phase 3 trials.

Catch up on important pain management news from the month of July.

Researchers analyzed the prominence of opioid and methadone prescriptions for hospitalized newborns with substantial morbidities.

Dive in and learn more about the answers to yesterday’s quiz.

Test your knowledge of migraine therapies.

Check out these top featured stories from Drug Topics in June 2024.

Four abstracts presented at ASCO 2024 delved into cannabis and pain management, potential medication interactions, and symptom mitigation, in patients with cancer.

A poster presented at AHS 2024 found that older patients tended to have more vitamin deficiencies compared to younger patients.

Academic, corporate, and clinical institutions must empower pharmacists to deliver informed and compassionate care to LGBTQ individuals that matches the standard received by their heterosexual and cisgender peers.

Dive in and learn more about the answers to yesterday’s quiz.

Test your knowledge different headache types.

Check out this list of resources to share with patients who are managing a migraine or other headache diagnosis.